The US Food and Drug Administration (FDA) has cleared Carestream's new lesion management module, designed to help enhance both diagnostic confidence and radiologist productivity.
The new tool, which is designed for use with the company's Vue PACS workstation, assess oncology patients by enabling semi-automatic tracking and segmentation of lesions from modalities and other vendors' PACS systems.
Radiologists can easily navigate and diagnose by viewing anatomical bookmarks produced from each measurement of lesion within the exam.
In addition, the lesion management tool can generate comprehensive oncology imaging reports in accordance to Response Evaluation Criteria in Solid Tumors (RECIST) industry standards, allowing for clearer and more meaningful communication and collaboration between radiologists, oncologists and referring physicians.
Carestream healthcare information solutions global marketing manager Cristine Kao said the comparison results are displayed with each exam and can be embedded into the final diagnostic report for other clinicians for review.
"The proven volumetric registration combined with the new lesion management feature in our Vue PACS synchronizes views from current and prior exams, which makes it much faster and easier for radiologists to measure and compare lesions, as well as tumors, nodules and other anatomical structures," Kao added.
